Deals
Ascletis Draws GIC to First Pre-Profit Biotech IPO in Hong Kong
This article is for subscribers only.
Ascletis Pharma Inc., the first biotech company to take advantage of new Hong Kong listing rules, is seeking to raise as much as $457 million in an initial public offering in the city.
The company is offering 224.1 million shares at HK$12 to HK$16 apiece, according to terms for the deal obtained by Bloomberg. Singapore sovereign wealth fund GIC Pte agreed to buy $75 million of stock as a cornerstone investor, the terms show.